Insider Trading
| MIST Stock | USD 2.36 0.11 4.89% |
Slightly above 54% of Milestone Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Milestone Pharmaceuticals stock suggests that some investors are interested at this time. Milestone Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Milestone Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Milestone |
Filed transaction by Milestone Pharmaceuticals Executive. Insider Public Trading
Read at macroaxis.com
Milestone Pharmaceuticals Fundamental Analysis
We analyze Milestone Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Milestone Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Milestone Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Milestone Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Milestone Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Milestone Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Milestone Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Milestone Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Milestone Pharmaceuticals Related Equities
| DMAC | DiaMedica Therapeutics | 1.69 | ||||
| SCPH | Scpharmaceuticals | 1.14 | ||||
| SPRO | Spero Therapeutics | 0.98 | ||||
| DAWN | Day One | 0.72 | ||||
| NAMS | NewAmsterdam Pharma | 0.39 | ||||
| IKT | Inhibikase Therapeutics | 0.31 | ||||
| TERN | Terns Pharmaceuticals | 0.18 | ||||
| CGEM | Cullinan Oncology | 0.16 | ||||
| HOOK | Hookipa Pharma | 0.50 | ||||
| GLUE | Monte Rosa | 1.14 | ||||
| CMPX | Compass Therapeutics | 2.03 | ||||
| ONCY | Oncolytics Biotech | 2.15 | ||||
| BOLT | Bolt Biotherapeutics | 5.26 | ||||
| IVA | Inventiva | 5.73 | ||||
| MCRB | Seres Therapeutics | 6.74 | ||||
| CHRS | Coherus BioSciences | 8.00 | ||||
| XFOR | X4 Pharmaceuticals | 9.88 |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.